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A B S T R A C T
Introduction: Epilepsy prevalence is 0.27–1.7% in general population. However, higher ﬁgures have been
reported in Multiple Sclerosis (MS) patients, suggesting this association is not coincidental.
Methods: We retrospectively reviewed the records of MS patients seen between 2009 and 2012 at
Pontiﬁcia Universidad Cato´lica of Chile’s Multiple Sclerosis Center.
Results: Of 310 MS patients, ten had the diagnosis of epilepsy (3.2%). These patients were younger, and
had an earlier onset of symptoms of MS compared to the group without epilepsy (32 vs. 40 years, p = 0.04
and 25 vs. 32 years, p = 0.02, respectively). In 4 patients, seizures were the ﬁrst MS symptom and the
most frequent seizure type was partial secondary generalized (6 patients). MRI showed cortical lesions in
all patients. Patients with poor epilepsy control (frequent seizures or development of status epilepticus)
had lower brain volumes and worse cognitive performance. All patients received antiepileptic drugs as
well as immunomodulatory therapy.
Conclusion: Patients with epilepsy and MS are younger and have an earlier onset of symptoms. Since
most seizures were partial, the presence of cortical lesions and progressive brain atrophy could probably
be the pathophysiological mechanism underlying this association.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy prevalence in the general population ranges from 0.27
to 1.7%.1 However, in patients with multiple sclerosis (MS), an
average of 2.3% has been described (range 0.5–10.8%),2 suggesting
this association is not coincidental. These ﬁndings were conﬁrmed
recently in a population study that included more than 5000 MS
patients.3
The pathophysiological mechanisms that explain this associa-
tion are still under investigation. Studies based on new magnetic
resonance imaging (MRI) sequences have shown more cortical
lesions and atrophy in patients affected by both disorders4,5
perhaps explaining the higher epilepsy prevalence in MS patients.
The aim of this study is to determine the prevalence of epilepsy
in our MS patients and comprehend the possible underlying
mechanisms involved.* Corresponding author at: Marcoleta 350 28 piso, Santiago, Chile.
Tel.: +56 2 23543316.
E-mail addresses: reinaldouribe@gmail.com, ethelciampi@gmail.com
(R. Uribe-San-Martı´n).
1 U-S-M.R. and C-D.E. equally contributed to this paper.
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http://dx.doi.org/10.1016/j.seizure.2013.09.0082. Materials and methods
We retrospectively reviewed the records of all patients fulﬁlling
MS diagnostic criteria or clinically isolated syndrome (CIS),6 seen
at the Multiple Sclerosis Center of the Pontiﬁcal Catholic University
of Chile, between 2009 and 2012. The study protocol was approved
by the Ethics Committee of the Faculty of Medicine.
Epilepsy diagnosis and seizures types were established
according to the classiﬁcation of the International League Against
Epilepsy (ILAE, 1981). We evaluated the ﬁndings in standard
interictal EEGs (international system 10/20 and activated with
photo stimulation and hyperventilation) performed within the
ﬁrst week after the ﬁrst seizure. We reviewed the incidence of
cortical lesions in MRI (diffusion weighted image (DWI), ﬂuid
attenuated inversion recovery (FLAIR), double inversion recovery
(DIR) and T1 with gadolinium, using 1.5 T with 5 mm thick slices,
and 2.5 mm separation between cuts). We evaluated brain volume
using manual measurements with ‘‘NIH Image J’’ public domain
software available at the National Institute of Health homepage.
We performed cognitive evaluation using D-KEFS for verbal
ﬂuency, BTACT for processing speed and Digit Span from NeBHis
for attention evaluation.
Gender, current age, age at onset, initial symptoms, clinical
course and duration of MS, expanded disability scale status of
Kurtzke (EDSS), immunomodulatory therapy and use of antiepi-
leptic drugs (AED) were also analyzed.vier Ltd. All rights reserved.
Table 1
Clinical characteristics of MS patients with and without epilepsy.
MS patients with epilepsy (10) MS patients without epilepsy (300) p-Value
Gender (%)
Female 44 70 0.18
Male 56 30
Current age (X years, range) 32 (19–42) 40 (15–82) 0.04
Age at onset (X years, range) 25 (15–40) 32 (12–62) 0.02
Duration of MS (X years, range) 7 (0–27) 8 (0–42) 0.35
Clinical course (%)
RR 60 67 0.74
SP 30 13 0.35
PP 0 10
CIS 10 10 1
Immunomodulatory therapy (%)
Yes 100 66 0.03
No 0 34
EDSS (%)
0–4.0 80 80 1
4.5–6.5 20 13 0.63
>7.0 0 7
The table describes the different characteristics of patients with MS. X, average; RR, relapsing remitting; SP, secondary progressive; PP, primary progressive; CIS, clinical
isolated syndrome; EDSS, expanded disability status scale of Kurtzke. Bold numbers highlight p < 0.05.
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Mann–Whitney test for continuous variables were obtained using
the SPSS Statistics 20.0 program. Differences were considered
signiﬁcant at p < 0.05.
3. Results
3.1. Clinical features
We found a total of 310 patients, 280 of them with deﬁnite
diagnosis of MS and 30 of CIS. Ten patients (3.2%, 10/310), also have
the diagnosis of epilepsy. In analyzing the demographic variables
between groups of patients with and without epilepsy, we found
no signiﬁcant differences in gender, duration of disease, clinical
course or EDSS. Both current age and age at MS onset were
signiﬁcantly lower in the group with epilepsy compared to the
group without epilepsy (32 vs. 40 years, p = 0.04 and 25 vs. 32
years, p = 0.02, respectively). In addition, all patients with epilepsy
and MS were receiving immunomodulatory therapy compared to
66% of MS patients without epilepsy (p = 0.03) (Table 1).Table 2
Clinical and laboratory ﬁndings in patients with epilepsy and MS.
Age/sex FH Onset MS Seizure type MS debut EEG 
1 31/M No 31 SPS Yes Normal 
2 36/M No 23 sGTCS No Focal slow and spike
SE Bilateral frontotemp
3 32/F No 30 SPS No Focal synchronic slo
CPS Anterior bilateral 
4 35/F No 20 sGTCS No Normal 
SE
5 39/M No 28 sGTCS No Normal 
6 22/M No 20 GTCS No Normal 
7 19/M No 16 sGTCS Yes normal 
8 42/F No 15 GTCS No Slow 
Nocturnal Right hemisphere
9 41/F No 40 sGTCS Yes Focal slow 
Left frontotemporal
10 22/F No 22 sGTCS Yes Normal 
The table describes different characteristics of the patients with epilepsy and MS. M, mal
partial seizure; sGTCS, secondarily generalized tonic–clonic seizure; GTCS, generalized to
debut MS, seizures were the debut symptom of their MS. MRI Gd +/, localization of co
sclerosis clinical course; CIS, clinical isolated syndrome; RR, relapsing remitting; SP
immunomodulatory therapy; INF, interferon beta; RTX, rituximab, CPX, copaxone, MTX,
clobazam; OXC, oxcarbazepine; PHT, phenytoin; LTG, lamotrigine; TPM, topiramate.3.2. Patients with multiple sclerosis and epilepsy
Ten patients (5 men) met diagnostic criteria for epilepsy and
MS/CIS. None had had seizures before MS diagnosis and they
occurred as the ﬁrst symptom (4 patients) or during the course of
the disease. Partial onset with secondary generalization was the
most frequent type of seizure (6 patients). Two patients had
generalized tonic clonic seizures and another 2 had only partial
seizures. Notably, 2 patients had convulsive status epilepticus
during their evolution. Interictal EEG showed focal abnormalities
in 4 patients. All patients had cortical lesions on MRI (supplemen-
tary ﬁgure 1). When comparing good versus poor epilepsy control
(7 vs. 3 patients respectively), considering poor control as frequent
seizures or status epilepticus, we found lower brain volumes
(average 28% less volume, p = 0.01) and worse cognitive perfor-
mance (32% worse scores, p = 0.03) in the last group (supplemen-
tary ﬁgure 2). All patients with epilepsy and MS were receiving
immunomodulatory and anticonvulsant treatment (Table 2).
Supplementary material related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.seizure.2013.
09.008.MRI Gd MS CC EDSS IT AED
Right parietooccipital  CIS 0 INF LEV
s Bilateral frontotemporal  SP 5 RTX VPA CLB
oral
w Bilateral frontotemporal RR 0 INF LEV
Left parietal 
Bilateral frontoparietal  SP 5.5 MTX LEV
Bilateral frontoparietal  RR 0 INF OXC PHT
Right parietal  RR 0 INF LEV
Bilateral frontoparietal temporal  RR 0 INF PHT
Right frontotemporal  SP 3.5 CPX LEV
Left frontal + RR 1 INF LTG
Left parietooccipital + RR 0 INF TPM
e; F, female; FH, family history of epilepsy; SPS, simple partial seizure; CPS, complex
nic–clonic seizure; SE, status epilepticus. Onset MS, age at onset of symptoms of MS;
rtical lesion in 1.5 T MRI with/without gadolinium enhancement; MS CC, multiple
, secondary progressive; EDSS, expanded disability status scale of Kurtzke; IT,
 mitoxantrone; AED, antiepileptic drug; LEV, levetiracetam; VPA, valproic acid; CLB,
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The epilepsy prevalence in our MS patients’ cohort was 3.2%.
This is the ﬁrst description in Chile. This ﬁnding is similar to
previous studies with larger number of patients. Catenoix
described prevalence of 2% in a study that included 5041 patients
with MS,3 which is similar to the ﬁndings shown in a review of 29
clinical series, with a total of 17,239 MS patients and an average
prevalence of seizures of 2.3% with a range from 0.5 to 10.8%.2 It is
noteworthy that all of our patients met diagnostic criteria for
epilepsy and had no seizures before being diagnosed with MS. In
this regard, most data found in the literature correspond to the
prevalence of seizures, which might not reﬂect epilepsy prevalence
which could be even lower. Adjusting the epilepsy prevalence to
age, these values are about three times higher than those in the
general population.7,8 However, prevalence found in our cohort
may not accurately reﬂect our country statistics, due to the limited
retrospective design we used, and because our hospital is a referral
center for both MS and epilepsy in Chile.
In some cases, seizures may not be associated with MS as the
sole cause. In Catenoix’s series, only in 67 of the 102 patients who
had had a seizure it was found that MS was the only probable
cause. Some authors suggest that the occurrence of epilepsy in
these patients could be correlated with the clinical course or
severity of MS. However, we found no correlation with different
clinical courses, EDSS, neither with the use of different immuno-
modulators, including interferon beta, as previously reported.2
The pathophysiology basis of seizures in MS patients could be
explained whether these occur during a relapse or regardless.8
In one case, seizures are associated to inﬂammatory cortical
lesions, as observed with DIR sequences.5 As younger patients
present with more inﬂammatory lesions, this could explain the fact
that our cohort of patients was younger and had an earlier onset of
MS, including seizures as the ﬁrst manifestation of the demyelin-
ating disease.10 Additionally, all types of seizures have been
described in patients with MS, being those with partial onset the
most frequent (62–67%), corresponding to almost twice as
observed in patients with epilepsy in general.2,3 The predominance
of partial seizures and focal paroxysmal activity in the EEG
supports the role of focal inﬂammatory lesions.
Another scenario occurs, when cortical atrophy and neurode-
generation develop as the expression of the ongoing epileptogenic
processes, as seen in patients experiencing seizures, regardless of a
relapse.8 Patients with poor epilepsy control (including status
epilepticus) had signiﬁcant lower brain volumes and worse
cognitive performances as compared with those with good
control. Although most patients with epilepsy and MS developoligosymptomatic epilepsy,11,12 the higher frequency of status
epilepticus (20–30%)8,9 represents a relevant ﬁnding. While there
are still no randomized clinical trials that demonstrate the
superiority of a speciﬁc AED or that evaluate drugs that stop the
underlying epileptogenic processes, the possibility of predicting
poor epilepsy control could be a real breakthrough for prescribing
long term AED treatment in these patients, making the attempt to
halt the progression of brain atrophy and cognitive impairment.
5. Conclusions
Patients with epilepsy and MS have cortical inﬂammatory
lesions that would explain focal onset seizures during relapses or
as debut of MS. However, some patients build up numerous
epileptogenic processes, developing seizures away from relapses,
perpetuating neurodegeneration and cognitive impairment. These
patients should be the center for new treatment strategies
targeting the detention of the epileptogenic progression.
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